Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Hallucinogen
|
| gptkbp:actsOn |
serotonin receptor agonist
5-HT2A |
| gptkbp:category |
amphetamine
Hallucinogen recreational drug |
| gptkbp:chemicalFormula |
C18H22INO3
|
| gptkbp:developedBy |
gptkb:Ralf_Heim
|
| gptkbp:firstSynthesized |
2003
|
| https://www.w3.org/2000/01/rdf-schema#label |
25I-NBOMe
|
| gptkbp:IUPACName |
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
|
| gptkbp:legalStatus |
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK) illegal (many countries) |
| gptkbp:molecularWeight |
427.28 g/mol
|
| gptkbp:otherName |
Cimbi-5
N-benzyl-2C-I NBOMe-2CI |
| gptkbp:relatedTo |
gptkb:25B-NBOMe
gptkb:25C-NBOMe gptkb:2C-I |
| gptkbp:routeOfAdministration |
sublingual
nasal buccal |
| gptkbp:sideEffect |
seizures
hallucinations death (in overdose) vasoconstriction |
| gptkbp:usedFor |
recreational drug
|
| gptkbp:bfsParent |
gptkb:NBOMe_series
|
| gptkbp:bfsLayer |
7
|